A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-Stage or Locally Advanced Breast Cancer. This evidence concerns the gene ERBB2 and breast cancer.